Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Koskensalo, Selja ^a   Hagström, Jaana ^b   Linder, Nina ^c   Lundin, Mikael ^c   Sorsa, Timo ^c   Louhimo, Johanna ^a   Haglund, Caj ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Colorectal cancer; Immunohistochemistry; MMP 2; MMP 8; MMP 9; Prognosis

Indexed keywords

GELATINASE A; GELATINASE B; NEUTROPHIL COLLAGENASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; WORLD HEALTH ORGANIZATION;

EID: 84870551032     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-24     Document Type: Article

References (34)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 2 69 90 10.3322/caac.20107 21296855
2. Pathology report in colon cancer: what is prognostically important? Compton CC, Dig Dis 1999 17 2 67 79 10.1159/000016908 10545712
3. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C, Arch Pathol Lab Med 2000 124 7 979 994 10888773
4. Clinicopathologic characteristics and outcomes of patients with obstructive colorectal cancer. Yang Z, Wang L, Kang L, Xiang J, Peng J, Cui J, Huang Y, Wang J, J Gastrointest Surg 2011 15 7 1213 1222 10.1007/s11605-011- 1563-1 21584821
5. Outcome of acutely perforated colorectal cancers: experience of a single district general hospital. Anwar MA, D'Souza F, Coulter R, Memon B, Khan IM, Memon MA, Surg Oncol 2006 15 2 91 96 10.1016/j.suronc.2006.09.001 17049848
6. Role of desmoplasia in recurrence of stage II colorectal cancer within five years after surgery and therapeutic implication. Crispino P, De Toma G, Ciardi A, Bella A, Rivera M, Cavallaro G, Polistena A, Fornari F, Unim H, Pica R, Cassieri C, Mingazzini PL, Paoluzi P, Cancer Invest 2008 26 4 419 425 10.1080/07357900701788155 18443963
7. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F, Science 2006 313 5795 1960 1964 10.1126/science.1129139 17008531
8. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM, J Pathol 1997 182 3 318 324 10.1002/(SICI)1096-9896(199707)182:3<318::AID- PATH862>3.0.CO;2-6 9349235
9. Matrix metalloproteinases and the development of cancer. Coussens LM, Werb Z, Chem Biol 1996 3 11 895 904 10.1016/S1074-5521(96)90178-7 8939708
10. The collagen substrate specificity of human neutrophil collagenase. Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG, J Biol Chem 1987 262 21 10048 10052 3038863
11. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. Matsuyama Y, Takao S, Aikou T, J Surg Oncol 2002 80 2 105 110 10.1002/jso.10106 12173379
12. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Papadopoulou S, Scorilas A, Arnogianaki N, Papapanayiotou B, Tzimogiani A, Agnantis N, Talieri M, Tumour Biol 2001 22 6 383 389 10.1159/000050641 11786732
13. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O, Laato M, Int J Cancer 2007 121 4 714 723 10.1002/ijc.22747 17455256
14. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. Zeng ZS, Huang Y, Cohen AM, Guillem JG, J Clin Oncol 1996 14 12 3133 3140 8955659
15. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E, Mirtsou-Fidani V, Invasion Metastasis 1997 17 3 158 168 9702942
16. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, Specterman S, de Kier Joffe EB, Pallotta MG, Puricelli LI, Lastiri J, J Surg Oncol 2006 93 2 151 160 10.1002/jso.20413 16425303
17. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, Sweep FC, Puente XS, Lopez-Otin C, Cancer Res 2008 68 8 2755 2763 10.1158/0008-5472.CAN-07-5154 18413742
18. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D, Cancer Res 2004 64 5 1687 1694 10.1158/0008-5472.CAN-03-2047 14996728
19. Staging of colorectal cancer. The Australian clinico-pathological staging (ACPS) system compared with Dukes' system. Davis NC, Evans EB, Cohen JR, Theile DE, Dis Colon Rectum 1984 27 11 707 713 10.1007/BF02554593 6499604
20. Effects of tetracyclines on neutrophil, gingival and salivary collagenase. A functional and western-blot assessment with special reference to their cellular sources in periodontal disease. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YT, Ann N Y Acad Sci 1994 732 112 131 10.1111/j.1749-6632.1994.tb24729.x 7978785
21. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjanen S, Syrjanen K, Pyrhonen S, J Gastrointest Cancer 2009 40 3-4 91 97 19921474
22. Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer. Koumura H, Sugiyama Y, Kunieda K, Saji S, Gan To Kagaku Ryoho 1997 24 Suppl 2 324 331 9263524
23. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells-associations with histopathology and patients outcome. Jensen SA, Vainer B, Bartels A, Brunner N, Sorensen JB, Eur J Cancer 2010 46 18 3233 3242 10.1016/j.ejca.2010.07.046 20801641
24. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J, J Natl Cancer Inst 1993 85 7 574 578 10.1093/jnci/85.7.574 8384265
25. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T, Clin Cancer Res 2004 10 9 3110 3116 10.1158/1078-0432. CCR-03-0530 15131051
26. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW, Br J Cancer 1996 74 3 413 417 10.1038/bjc.1996.374 8695357
27. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M, Br J Cancer 2001 84 11 1488 1496 10.1054/bjoc.2001.1810 11384099
28. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H, Jpn J Cancer Res 1997 88 1 72 81 10.1111/j.1349-7006.1997.tb00304.x 9045899
29. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Saito K, Takeha S, Shiba K, Matsuno S, Sorsa T, Nagura H, Ohtani H, Int J Cancer 2000 86 1 24 29 10.1002/(SICI)1097- 0215(20000401)86:1<24::AID-IJC4>3.0.CO;2-A 10728590
30. Tissue microarray technology for high-throughput molecular profiling of cancer. Kallioniemi OP, Wagner U, Kononen J, Sauter G, Hum Mol Genet 2001 10 657 662 10.1093/hmg/10.7.657 11257096
31. Host expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in normal colon tissue affects metastatic potential of colorectal cancer. Masuda H, Aoki H, Dis Colon Rectum 1999 42 3 393 397 10.1007/BF02236360 10223763
32. Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer. Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T, Gynecol Oncol 1999 75 1 91 98 10.1006/gyno.1999.5533 10502432
33. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T, Br J Cancer 2003 89 7 1270 1275 10.1038/sj.bjc.6601238 14520459
34. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A, Am J Clin Oncol 2008 31 1 55 63 10.1097/COC.0b013e318068b4e2 18376229